4 results match your criteria: "The First Peoples' Hospital of Lanzhou[Affiliation]"
Chem Biol Interact
January 2022
Department of Surgical Oncology, The First Peoples Hospital of Lanzhou, Lanzhou, 730050, China. Electronic address:
This study examines the hepatoprotective activity of naringin loaded solid nanoparticles (NRG-SLNs) and compared with free naringin (FNRG) against aflatoxin B1 (AFB1) induced hepatocellular carcinoma. The liver's self-healing ability was studied using a self-recovery group that received no therapy. Following AFB1 therapy, rats were given NRG-SLNs produced using the ion-gelation technique.
View Article and Find Full Text PDFMinerva Med
February 2024
Department of Respiratory and Critical Care, The First Peoples' Hospital of Lanzhou, Lanzhou, China.
Arch Med Res
July 2021
Department of Cardiology, The First Peoples Hospital of Lanzhou, Lanzhou, P.R. China. Electronic address:
Objective: This research was designed to investigate the function of miR-1275 in hypoxia/reoxygenation (H/R)-induced myocardial injury and its in-depth mechanism.
Methods: Firstly, the differential expression of miR-1275 in patients with heart failure and healthy control were analyzed based on Gene Expression Omnibus (GEO) database. Then H/R model was constructed in vitro with AC16 cells.
Med Sci Monit
October 2019
Department of Respiration, The First Peoples' Hospital of Lanzhou City, Lanzhou, Gansu, China (mainland).
BACKGROUND Patients with advanced non-small cell lung cancer (NSCLC) treated with cisplatin, also termed cis-diamminedichloroplatinum (CDDP) or diamminedichloroplatinum (DDP), may develop chemoresistance. This study aimed to investigate the role of long non-coding RNA (lncRNA) X-inactive specific transcript (XIST) and multidrug resistance-1 (MDR1) in tumor tissue samples and the chemoresistant human NSCLC cell lines, H460/DDP and A549/DDP, and in a murine A549/DDP tumor xenograft. MATERIAL AND METHODS Tissue samples were from patients with NSCLC who responded cisplatin (DDP-sensitive) (n=24), patients with NSCLC unresponsive to cisplatin (DDP-resistant) (n=30), and normal lung tissue (n=25).
View Article and Find Full Text PDF